EPHB4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL130637	0.81	18/20
SCHEMBL130466	0.76	17/20
SCHEMBL130418	0.73	17/20
SCHEMBL130620	0.67	17/20
SCHEMBL234181	0.80	16/20
SCHEMBL130500	0.76	16/20
SCHEMBL12162	0.74	16/20
SCHEMBL129883	0.74	16/20
SCHEMBL130481	0.71	16/20
SCHEMBL129599	0.59	16/20
SCHEMBL10811	0.57	16/20
SCHEMBL130595	0.73	15/20
SCHEMBL129501	0.65	15/20
SCHEMBL129811	0.63	15/20
SCHEMBL129822	0.63	15/20
SCHEMBL129595	0.62	15/20
SCHEMBL129826	0.60	15/20
SCHEMBL129581	0.59	15/20
SCHEMBL130636	0.58	15/20
SCHEMBL149180	0.55	15/20

Clinical trials — most relevant to EPHB4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors	PHASE1/PHASE2	COMPLETED
PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)	PHASE2	COMPLETED
Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）	PHASE2	RECRUITING
Study of Anlotinib Plus Chemoradiotherapy in Patients With Locally Advanced NSCLC	PHASE1/PHASE2	UNKNOWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy	PHASE2	COMPLETED
Neoadjuvant GW572016 to Treat Breast Cancer	PHASE2	COMPLETED
Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer	PHASE1/PHASE2	COMPLETED
Safety and Efficacy of the PAINLESS Nerve Growth Factor CHF6467 in Optic Pathway Glioma (OPG)	PHASE2	ACTIVE_NOT_RECRUITING
Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas	PHASE1	COMPLETED
Efavirenz for Patients With Alzheimer's Disease	PHASE1	COMPLETED
Choline Effects - Pre-symptomatic AD	PHASE1	COMPLETED
Isolation of Cells From Biopsy Tissue to Aid in Kidney Repair	PHASE1	WITHDRAWN
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
Changes in Skin Innervation of Neurologically Asymptomatic Type 2 Diabetic Patients: the Correlation With the Diabetic Parameters and Neurotrophins.	nan	UNKNOWN
Cytochrome P450 Epoxygenase Pathway Regulation of Macrophage Function	nan	COMPLETED
Establish Diagnostic and Prognostic Models for Preclinical AD Patients Based on Multimodal MRI, Behavioral, Genetic, and Plasma Biomarkers	nan	RECRUITING
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
The Locus Coeruleus, Norepinephrine and Cognitive Aging	nan	ACTIVE_NOT_RECRUITING
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Brain Tissue Integrity and Autonomic Function Alterations in Childhood OSA and ADHD, and After Adenotonsillectomy.	nan	UNKNOWN
Toxins Removal and Inflammatory State modulAtion During Online Hemodiafiltration: Comparison of Two Different Dialyzers	nan	UNKNOWN
Risk Burden of Lipoprotein Metabolic Gene Haplotypes	nan	COMPLETED
Genetic Biomarkers for the Response to Anti-VEGF (Vascular Endothelial Growth Factor).Treatment in Wet Age-related Macular Degeneration (Wet ARMD)	nan	COMPLETED
Susceptibility Genes in Autism Spectrum Disorders	nan	COMPLETED
Clinical Significance of DKK2 Protein in Cerebral Ischemia-reperfusion Injury	nan	UNKNOWN
Genetic Study of Newly Diagnosed Central Nervous System Tumors in Young Children	nan	COMPLETED
The Role of Gene Changes in Brain Tumor Formation and Growth	nan	COMPLETED
The Association Between Post-ERCP Acute Pancreatitis and Various Genetic Mutations	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a EPHB4 binder may also engage these)

Protein	Name	Similarity
O09127	—	1.000	O09127 →
P54761	—	1.000	P54761 →
P54754	—	1.000	P54754 →
EPHA8	Ephrin type-A receptor 8	1.000	landscape →
EPHB3	Ephrin type-B receptor 3	0.998	landscape →
P0C0K6	—	0.998	P0C0K6 →
Q1KL86	—	0.997	Q1KL86 →
P0C0K7	—	0.997	P0C0K7 →
Q8BYG9	—	0.997	Q8BYG9 →
O73878	—	0.997	O73878 →
Q06805	—	0.996	Q06805 →
EPHA2	Ephrin type-A receptor 2	0.996	landscape →
Q91735	—	0.996	Q91735 →
Q03145	—	0.996	Q03145 →
EPHA5	Ephrin type-A receptor 5	0.995	landscape →
TIE1	Tyrosine-protein kinase receptor Tie-1	0.995	landscape →
O08644	—	0.995	O08644 →
P54755	—	0.994	P54755 →
Q60750	—	0.994	Q60750 →
P54757	—	0.994	P54757 →
P51840	—	0.994	P51840 →
P55203	—	0.994	P55203 →
O73875	—	0.993	O73875 →
Q06806	—	0.993	Q06806 →
Q03146	—	0.993	Q03146 →
Q60629	—	0.993	Q60629 →
EPHA1	Ephrin type-A receptor 1	0.993	landscape →
Q63474	—	0.993	Q63474 →
P52785	—	0.993	P52785 →
O13146	—	0.992	O13146 →